Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2WE5K)

• Drug Name: Ceruletide Drug Info
• Synonyms: Caerulein; Cerulein; Ceruletida; Ceruletidum; Ceruletida [INN-Spanish]; Ceruletidum [INN-Latin]; Ceruletide (USAN/INN); Ceruletide [USAN:INN:BAN]; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide

Indication

Disease Entry	ICD 11	Status	REF
Caerulein stimulated gastric and pancreatic secretion	5A4Y	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]

• Therapeutic Class: Diagnostic Agents
• Cross-matching ID:
  PubChem CID: 16129675
  ChEBI ID: CHEMBL59219
  CAS Number: CAS 17650-98-5
  TTD Drug ID: DM2WE5K

Molecule-Related Drug Atlas

Drug(s) Targeting Gastrin/cholecystokinin type B receptor (CCKBR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pentagastrin	DMRCLZB	Diagnostic imaging	N.A.	Approved	[5]
GASTRAZOLE	DMO3ITF	Duodenal ulcer	DA63	Phase 3	[6]
Dexloxiglumide	DM52HUD	Pancreatic malfunction	DC30-DC3Z	Phase 2	[7]
Spiroglumide	DM7NJWY	Stomach disease	DA43-DA4Y	Phase 2	[8]
TT-223	DMCDMFP	Type-1 diabetes	5A10	Phase 2	[9]
Z 360	DM2M80G	Discovery agent	N.A.	Phase 2	[10]
S-0509	DM4KWEF	Ulcerative colitis	DD71	Phase 2	[11]
YF-476	DM54MAJ	Stomach ulcer	DA60.Z	Phase 2	[12]
Itriglumide	DM5UFRO	Anxiety disorder	6B00-6B0Z	Phase 2	[13]
Demogastrin	DMTULGS	Thyroid cancer	2D10	Phase 1	[14]

Drug(s) Affected By Collagen alpha-1(I) chain (COL1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[15]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[16]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[17]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[18]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[19]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[20]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[21]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[22]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[23]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[24]

Drug(s) Affected By Parathyroid hormone-related protein (PTHLH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[25]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[26]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[27]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[28]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[29]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[30]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[32]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[34]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastrin/cholecystokinin type B receptor (CCKBR)	TTVFO0U	GASR_HUMAN	Agonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Gene/Protein Processing	[4]
Parathyroid hormone-related protein (PTHLH)	OTI1JF13	PTHR_HUMAN	Gene/Protein Processing	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7589).
• [3] Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.
• [4] Acinar cell-specific knockout of the PTHrP gene decreases the proinflammatory and profibrotic responses in pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G533-49. doi: 10.1152/ajpgi.00428.2013. Epub 2014 Jul 17.
• [5] Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21.
• [6] Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 April 24; 94(8): 1107-1115.
• [7] Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
• [8] Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9.
• [9] The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.
• [10] Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gen... Biol Pharm Bull. 2010;33(2):216-22.
• [11] Selective action of a CCK-B/gastrin receptor antagonist, S-0509, on pentagastrin-, peptone meal- and beer-stimulated gastric acid secretion in dogs. Aliment Pharmacol Ther. 2000 Apr;14(4):479-88.
• [12] CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. Scand J Gastroenterol. 2004 Sep;39(9):886-90.
• [13] Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem. 2007; 7(12): 1211-1231.
• [14] Demonstration of new sites of expression of the CCK-B/gastrin receptor in pancreatic acinar AR42J cells using immunoelectron microscopy. Regul Pept. 1999 Oct 22;84(1-3):81-9.
• [15] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [16] Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
• [17] Patterns of some extracellular matrix gene expression are similar in cells from cleft lip-palate patients and in human palatal fibroblasts exposed to diazepam in culture. Toxicology. 2009 Mar 4;257(1-2):10-6. doi: 10.1016/j.tox.2008.12.002. Epub 2008 Dec 9.
• [18] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [19] Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
• [20] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [21] The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am. 2001 Feb;83(2):201-11. doi: 10.2106/00004623-200102000-00007.
• [22] Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006 Apr;54(4):1298-308. doi: 10.1002/art.21723.
• [23] Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy. Invest Ophthalmol Vis Sci. 2012 Aug 31;53(9):5921-9. doi: 10.1167/iovs.12-9646.
• [24] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [25] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [26] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [27] All-trans retinoic acid induced hypercalcemia in a patient with acute promyelocytic leukemia: its relation to increased PTH-rP. Int J Hematol. 1994 Feb;59(2):143-4.
• [28] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [29] Parathyroid hormone-related protein varies with sex and androgen status in nonsmall cell lung cancer. Cancer. 2007 Sep 15;110(6):1313-20. doi: 10.1002/cncr.22922.
• [30] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [31] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [32] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [33] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [34] Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm Metab Res. 2005 Oct;37(10):593-601. doi: 10.1055/s-2005-870525.